ORIGINAL ARTICLE |
|
Year : 2021 | Volume
: 4
| Issue : 1 | Page : 30-34 |
|
The effect of treatment duration on metabolic parameters in patients with prolactinoma: A prospective longitudinal study
Mehrnaz Imani1, Rowshanak Abbasi1, Fatemeh Golgiri1, Alireza Khajavi2, Hamideh Akbari3
1 Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran 2 Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran 3 Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran; Clinical Research Development Unit, Sayad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran
Correspondence Address:
Dr. Mehrnaz Imani Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran Iran
Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jdep.jdep_2_19
|
|
Background: Hyperprolactinemia is associated with changes in body composition and metabolic abnormalities. Normalization of prolactin (PRL) has been suggested to reverse these abnormalities. The present study was designed to determine the effect of treatment duration on metabolism as well as metabolic alterations after treatment in comparison with baseline in patients with prolactinoma in Iranian individuals. Methods: In a prospective and longitudinal study, 27 consecutive patients with prolactinoma were assessed during 6 months. Anthropometric data and metabolic variables were studied at baseline and at 3 and 6 months after normalization of PRL. Results: In the present study, there was a statistically significant decrease of metabolic syndrome (Met.S) after 3 months (P = 0.01), with a further decline after 6 months (P < 0.001) of cabergoline therapy. Moreover, a statistically significant decline was seen in total cholesterol (P = 0.007 and P = 0.01 after 3 and 6 months, respectively) and uric acid (P = 0.05 and P = 0.03 after 3 and 6 months, respectively) after normalization of the serum PRL. Conclusions: We found a significant reduction in Met.S after normalization of PRL level in patients with prolactinoma. We suggest that it is important to consider the metabolic profile of patients with prolactinoma. Then, patients may benefit even at 3 months after treatment.
|
|
|
|
[FULL TEXT] [PDF]* |
|
|
|